Therefore, providing ART to TB patients with CD4 counts above 350 cells/μl is likely to have a similar prevention effect on HIV transmission as treating a random subset of HIV-infected individuals with a CD4 count above 350 cells/μl. The gene discussed is CD4; the disease is tuberculosis.